Monitoring the response to pharmacologic therapy in patients with stable chronic heart failure: Is BNP or NT-proBNP a useful assessment tool?

Clinical Biochemistry

Volumn 41, Issue 4-5, 2008, Pages 266-276

  Balion, Cynthia M ^a,b   McKelvie, Robert S ^b   Reichert, Sonja ^c   Santaguida, Pasqualina ^b   Booker, Lynda ^b   Worster, Andrew ^b   Raina, Parminder ^b   McQueen, Matthew J ^a,b   Hill, Stephen ^a,b  

^a HAMILTON REGIONAL LABORATORY MEDICINE PROGRAM   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

BNP; Drugs; Heart failure; Monitoring; NT proBNP; Systematic review; Therapy

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOCHEMICAL MARKER; BRAIN NATRIURETIC PEPTIDE; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; METOPROLOL; PERINDOPRIL; VALSARTAN;

ARTICLE; DISEASE SEVERITY; DRUG MEGADOSE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; LOW DRUG DOSE; MORTALITY; PATIENT MONITORING; PRIORITY JOURNAL; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE;

CHRONIC DISEASE; HEART FAILURE; HUMANS; MONITORING, PHYSIOLOGIC; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 39149109920     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2007.10.006     Document Type: Article

References (36)

1. Johansen H., Strauss B., Arnold J.M., Moe G., and Liu P. On the rise: the current and projected future burden of congestive heart failure hospitalization in Canada. Can J Cardiol 19 (2003) 430-435
2. Thomas S., and Rich M.W. Epidemiology, pathophysiology, and prognosis of heart failure in the elderly. Clin Geriatr Med 23 (2007) 1-10
3. Arnold J.M., Howlett J.G., Dorian P., et al. Canadian Cardiovascular Society Consensus Conference recommendations on heart failure update 2007: prevention, management during intercurrent illness or acute decompensation, and use of biomarkers. Can J Cardiol 23 (2007) 21-45
4. Swedberg K., Cleland J., Dargie H., et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): the Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 26 (2005) 1115-1140
5. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Writing Committee to update the 2001 guidelines for the evaluation and management of heart failure). J Am Coll Cardiol 46 (2005) 1116-1143
6. Abdulla J., Kober L., and Torp-Pedersen C. Methods of assessing the functional status of patients with left ventricular systolic dysfunction in interventional studies: can brain natriuretic peptide measurement be used as surrogate for the traditional methods?. [see comment]. [Review] [51 refs]. Cardiovasc Drugs Ther 18 (2004) 219-224
7. Doust J.A., Pietrzak E., Dobson A., and Glasziou P. How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review. BMJ 330 (2005) 625-633
8. Balion C., Santaguida P., Hill S., et al. Testing for BNP and NT-proBNP in the diagnosis and prognosis of heart failure (2006), Agency for Healthcare Research and Quality, Rockville, MD
9. Karl J., Borgya A., Gallusser A., et al. Development of a novel, N-terminal-proBNP (NT-proBNP) assay with a low detection limit. Scand J Clin Lab Invest Suppl 230 (1999) 177-181
10. Hunt P.J., Richards A.M., Nicholls M.G., et al. Immunoreactive amino-terminal pro-brain natriuretic peptide (NT-PROBNP): a new marker of cardiac impairment. Clin Endocrinol (Oxf) 47 (1997) 287-296
11. Patrick Bossuyt L.I.P.G. Diagnostic test appraisal form. Screening and test evaluation program (STEP). Internet (1998). http://www.health.usyd.edu.au/step/about/appraisal.htm Available from: URL: http://www.health.usyd.edu.au/step/about/appraisal.htm
12. Konishi H., Nishio S., Tsutamoto T., Minouchi T., and Yamaji A. Serum carvedilol concentration and its relation to change in plasma brain natriuretic peptide level in the treatment of heart failure: a preliminary study. Int J Clin Pharmacol Ther 41 (2003) 578-586
13. Shiga T., Hosaka F., Wakaumi M., et al. Amiodarone decreases plasma brain natriuretic peptide level in patients with heart failure and ventricular tachyarrhythmia. Cardiovasc Drugs Ther 17 (2003) 325-333
14. Fung J.W., Yu C.M., Yip G., et al. Effect of beta blockade (carvedilol or metoprolol) on activation of the rennin-angiotensin-aldosterone system and natriuretic peptides in chronic heart failure. Am J Cardiol 92 (2003) 406-410
15. Troughton R.W., Frampton C.M., Yandle T.G., et al. Plasma amino-terminal B-type natriuretic peptide measured by Elecsys 2010 assay in a trial of hormone-guided treatment for heart failure. Clin Chem 49 (2003) 1212-1215
16. Anand I.S., Fisher L.D., Chiang Y.T., et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 107 (2003) 1278-1283
17. Latini R., Masson S., Anand I., et al. Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT). Circulation 106 (2002) 2454-2458
18. Yoshimura M., Mizuno Y., Nakayama M., et al. B-type natriuretic peptide as a marker of the effects of enalapril in patients with heart failure. Am J Med 112 (2002) 716-720
19. Stanek B., Frey B., Hulsmann M., et al. Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction. J Am Coll Cardiol 38 (2001) 436-442
20. Kawai K., Hata K., Takaoka H., Kawai H., and Yokoyama M. Plasma brain natriuretic peptide as a novel therapeutic indicator in idiopathic dilated cardiomyopathy during beta-blocker therapy: a potential of hormone-guided treatment. Am Heart J 141 (2001) 925-932
21. Troughton R.W., Frampton C.M., Yandle T.G., et al. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 355 (2000) 1126-1130
22. Brunner-La Rocca H.P., Weilenmann D., Kiowski W., et al. Within-patient comparison of effects of different dosages of enalapril on functional capacity and neurohormone levels in patients with chronic heart failure. Am Heart J 138 (1999) 654-662
23. Murdoch D.R., McDonagh T.A., Byrne J., et al. Titration of vasodilator therapy in chronic heart failure according to plasma brain natriuretic peptide concentration: randomized comparison of the hemodynamic and neuroendocrine effects of tailored versus empirical therapy. Am Heart J 138 (1999) 1126-1132
24. Thompson L.O., Skrabal C.A., Loebe M., et al. Plasma neurohormone levels correlate with left ventricular functional and morphological improvement in LVAD patients. J Surg Res 123 (2005) 25-32
25. Baruch L., Glazer R.D., Aknay N., et al. Morbidity, mortality, physiologic and functional parameters in elderly and non-elderly patients in the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J 148 (2004) 951-957
26. Yoshizawa A., Yoshikawa T., Nakamura I., et al. Brain natriuretic peptide response is heterogeneous during beta-blocker therapy for congestive heart failure. J Card Fail 10 (2004) 310-315
27. Krum H., Carson P., Farsang C., et al. Effect of valsartan added to background ACE inhibitor therapy in patients with heart failure: Results from Val-HeFT. Eur J Heart Fail 6 (2004) 937-945
28. Maggioni A.P., Anand I., Gottlieb S.O., et al. Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. J Am Coll Cardiol 40 (2002) 1414-1421
29. Sliwa K., Norton G.R., Kone N., et al. Impact of initiating carvedilol before angiotensin-converting enzyme inhibitor therapy on cardiac function in newly diagnosed heart failure. J Am Coll Cardiol 44 (2004) 1825-1830
30. Mills R.M. The failing heart and the hemodynamic response to vasodilator therapy. [Review] [12 refs]. Clin Cardiol 26 (2003) 257-258
31. Richards M., Nicholls M.G., Espiner E.A., et al. Comparison of B-type natriuretic peptides for assessment of cardiac function and prognosis in stable ischemic heart disease. J Am Coll Cardiol 47 (2006) 52-60
32. Wu A.H. Serial testing of B-type natriuretic peptide and NTpro-BNP for monitoring therapy of heart failure: the role of biologic variation in the interpretation of results. Am Heart J 152 (2006) 828-834
33. Jourdain P., Jondeau G., Funck F., et al. Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study. J Am Coll Cardiol 49 (2007) 1733-1739
34. Lainchbury J.G., Troughton R.W., Frampton C.M., et al. NTproBNP-guided drug treatment for chronic heart failure: design and methods in the "BATTLESCARRED" trial. Eur J Heart Fail 8 (2006) 532-538
35. Shah M.R., Claise K.A., Bowers M.T., et al. Testing new targets of therapy in advanced heart failure: the design and rationale of the strategies for tailoring advanced heart failure regimens in the outpatient setting: BRain NatrIuretic Peptide Versus the Clinical CongesTion ScorE (STARBRITE) trial. Am Heart J 150 (2005) 893-898
36. Brunner-La Rocca H.P., Buser P.T., Schindler R., et al. Management of elderly patients with congestive heart failure-design of the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF). Am Heart J 151 (2006) 949-955